Sana Biotechnology, Inc.

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

SANA$2.37+1.3%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

3. Segment reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by thechief operating decision-maker (CODM), the Company's Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business inone operating segment. When evaluating the Company's financial performance, the CODM reviews total expenses and expenses by function. Further, the CODM reviews the segment's assets based on total assets reported on the consolidated balance sheet.

The table below is a summary of the segment loss, including significant segment expenses (in thousands):

Three months ended June 30, · Six months ended June 30,
	2026		2025 (1)		2026	2025 (1)
(in thousands) · (in thousands)
Operating expenses:
Research, development, and laboratory		$10,591		$8,962		$20,649	$21,053
Facility costs		10,365		10,856		20,844	22,573
Support functions		6,911		6,901		14,179	15,070
Stock-based compensation		5,342		6,629		11,004	13,651
Technical operations and manufacturing		5,647		4,511		9,633	11,948
Other(2)		2,651		2,243		5,379	4,480
Research and development related success payments and contingent consideration		23,913		10,262		32,346	12,219
Impairment of long-lived assets		-		44,611		-	44,611
Total operating expenses		65,420		94,975		114,034	145,605
Loss from operations		(65,420)		(94,975)		(114,034)	(145,605)
Interest income, net		1,129		577		2,080	1,569
Other income, net		656		598		1,109	847
Net loss		$(63,635)		$(93,800)		$(110,845)	$(143,189)

(1) Certain amounts for the three and six months ended June 30, 2025 have been reclassified to conform to the presentation as of the three and six months ended June 30, 2026.

(2) Other includes licensing costs, consulting fees, insurance, and business taxes for the three and six months ended June 30, 2026 and 2025.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.